Incyte Corp office sign_ by Bo Shen via iStock Based in Wilmington, Delaware, Incyte Corporation (INCY) is a global biopharmaceutical company that discovers, develops, and commercializes innovative treatments for cancer, blood disorders, and immune-mediated diseases. The company's marketed therapies include JAKAFI for blood cancers, ICLUSIG for leukemia, PEMAZYRE for bile duct cancer, MONJUVI/MINJUVI for lymphoma, and NIKTIMVO for fibrotic disease. Incyte is also developing an extensive clinical pipeline to treat additional cancers, myeloproliferative neoplasms, inflammatory diseases, and rare disorders.

Incyte Corp office sign_ by Bo Shen via iStock Based in Wilmington, Delaware, Incyte Corporation (INCY) is a global biopharmaceutical company that discovers, develops, and commercializes innovative treatments for cancer, blood disorders, and immune-mediated diseases. The company's marketed therapies include JAKAFI for blood cancers, ICLUSIG for leukemia, PEMAZYRE for bile duct cancer, MONJUVI/MINJUVI for lymphoma, and NIKTIMVO for fibrotic disease. Incyte is also developing an extensive clinical pipeline to treat additional cancers, myeloproliferative neoplasms, inflammatory diseases, and rare disorders.

Incyte Corp office sign_ by Bo Shen via iStock Based in Wilmington, Delaware, Incyte Corporation (INCY) is a global biopharmaceutical company that discovers, develops, and commercializes innovative treatments for cancer, blood disorders, and immune-mediated diseases. The company's marketed therapies include JAKAFI for blood cancers, ICLUSIG for leukemia, PEMAZYRE for bile duct cancer, MONJUVI/MINJUVI for lymphoma, and NIKTIMVO for fibrotic disease. Incyte is also developing an extensive clinical pipeline to treat additional cancers, myeloproliferative neoplasms, inflammatory diseases, and rare disorders.

Incyte Corp office sign_ by Bo Shen via iStock Based in Wilmington, Delaware, Incyte Corporation (INCY) is a global biopharmaceutical company that discovers, develops, and commercializes innovative treatments for cancer, blood disorders, and immune-mediated diseases. The company's marketed therapies include JAKAFI for blood cancers, ICLUSIG for leukemia, PEMAZYRE for bile duct cancer, MONJUVI/MINJUVI for lymphoma, and NIKTIMVO for fibrotic disease. Incyte is also developing an extensive clinical pipeline to treat additional cancers, myeloproliferative neoplasms, inflammatory diseases, and rare disorders.

Incyte Corp office sign_ by Bo Shen via iStock Based in Wilmington, Delaware, Incyte Corporation (INCY) is a global biopharmaceutical company that discovers, develops, and commercializes innovative treatments for cancer, blood disorders, and immune-mediated diseases. The company's marketed therapies include JAKAFI for blood cancers, ICLUSIG for leukemia, PEMAZYRE for bile duct cancer, MONJUVI/MINJUVI for lymphoma, and NIKTIMVO for fibrotic disease. Incyte is also developing an extensive clinical pipeline to treat additional cancers, myeloproliferative neoplasms, inflammatory diseases, and rare disorders.

Incyte Corp office sign_ by Bo Shen via iStock Based in Wilmington, Delaware, Incyte Corporation (INCY) is a global biopharmaceutical company that discovers, develops, and commercializes innovative treatments for cancer, blood disorders, and immune-mediated diseases. The company's marketed therapies include JAKAFI for blood cancers, ICLUSIG for leukemia, PEMAZYRE for bile duct cancer, MONJUVI/MINJUVI for lymphoma, and NIKTIMVO for fibrotic disease. Incyte is also developing an extensive clinical pipeline to treat additional cancers, myeloproliferative neoplasms, inflammatory diseases, and rare disorders.

Incyte Corp office sign_ by Bo Shen via iStock Based in Wilmington, Delaware, Incyte Corporation (INCY) is a global biopharmaceutical company that discovers, develops, and commercializes innovative treatments for cancer, blood disorders, and immune-mediated diseases. The company's marketed therapies include JAKAFI for blood cancers, ICLUSIG for leukemia, PEMAZYRE for bile duct cancer, MONJUVI/MINJUVI for lymphoma, and NIKTIMVO for fibrotic disease. Incyte is also developing an extensive clinical pipeline to treat additional cancers, myeloproliferative neoplasms, inflammatory diseases, and rare disorders.

Incyte Corp office sign_ by Bo Shen via iStock Based in Wilmington, Delaware, Incyte Corporation (INCY) is a global biopharmaceutical company that discovers, develops, and commercializes innovative treatments for cancer, blood disorders, and immune-mediated diseases. The company's marketed therapies include JAKAFI for blood cancers, ICLUSIG for leukemia, PEMAZYRE for bile duct cancer, MONJUVI/MINJUVI for lymphoma, and NIKTIMVO for fibrotic disease. Incyte is also developing an extensive clinical pipeline to treat additional cancers, myeloproliferative neoplasms, inflammatory diseases, and rare disorders.

– Total revenue of $73 million in 2Q26, a 92% year-over-year increase – – Revuforj ® (revumenib) net revenue of $54.7 million in 2Q26, a 91% year-over-year increase – – Niktimvo™ (axatilimab-csfr) net revenue of $60.3 million in 2Q26, a 67% year-over-year increase, resulting in Syndax collaboration

Australia's TGA has approved NIKTIMVO for chronic graft-versus-host disease after two prior therapies fail. Here's what the 74% response rate means for patients.

The Therapeutic Goods Administration in Australia has granted approval to NIKTIMVO (axatilimab) for chronic graft-versus-host disease. This first-in-class therapy marks a significant advancement in treatment options.

NIKTIMVO® (axatilimab) approved by the Therapeutic Goods Administration (TGA) under Priority Review for the treatment of eligible Australian patients with chronic graft-versus-host disease[2] Australia becomes the first country to obtain Marketing Authorisation for NIKTIMVO since approval...

NIKTIMVO ® approved by the Therapeutic Goods Administration under Priority Review for the treatment of eligible Australian patients with chronic graft-versus-host disease Australia becomes the first country to obtain Marketing Authorisation for NIKTIMVO since approval by the US FDA Australian-led research played key role in the development of...

– Total revenue of $64.9 million in 1Q26, a 224% year-over-year increase – – Revuforj ® (revumenib) net revenue of $48.9 million in 1Q26, highlighting leadership in menin inhibition and increasing uptake in R/R NPM1m AML – – Niktimvo™ (axatilimab-csfr) net revenue of $55.1 million in 1Q26,

NIKTIMVO is a drug used to treat adults and children who weigh at least 88.2 pounds (40 kg) with chronic graft-versus-host disease (GVHD) who have received at least two prior treatments (systemic therapy) and required additional treatment.

Syndax (NASDAQ: SNDX) reported Q4 2025 revenue $68.7M and FY2025 revenue $172.4M, driven by Revuforj net sales of $44.2M in Q4 ($124.8M FY2025) and Niktimvo net sales of $56.0M in Q4 ($151.6M FY2025).The company had $394.1M in cash and equivalents at year-end, completed Phase 2 IPF enrollment for axatilimab, and expects 2026 R&D plus SG&A of ~$400M while targeting profitability from product and collaboration revenue.

Syndax (Nasdaq: SNDX) reported $45.9M total revenue for 3Q25, including $32.0M Revuforj net revenue and $13.9M collaboration revenue from Niktimvo. Revuforj prescriptions rose ~25% QoQ (~850 scripts) and Revuforj received FDA approval on Oct 24, 2025 and NCCN category 2A listing for R/R NPM1m AML. Incyte reported $45.8M Niktimvo net sales; Syndax recorded 50% product contribution. Cash, cash equivalents and investments were $456.1M, which the company expects will fund it to profitability. Reported 3Q25 net loss was $60.7M. Conference call held Nov 3, 2025.

Reported Monday, Nov 3 - 9:23am EST (TheFly subscription required to read more.)

Syndax (Nasdaq: SNDX) announced that 23 abstracts, including 6 oral presentations, featuring Revuforj (revumenib) and Niktimvo (axatilimab) data were accepted for presentation at the ASH Annual Meeting, Dec 6-9, 2025 in Orlando.Revumenib abstracts cover frontline and relapsed/refractory acute leukemia, combination regimens (venetoclax + decitabine/cedazuridine; intensive chemo; gilteritinib), real-world experience, and post-HSCT maintenance. Axatilimab abstracts address dosing feasibility, long-term therapy in R/R chronic GVHD, combination with ruxolitinib in newly diagnosed chronic GVHD, biomarker/pharmacodynamic analyses, and a Phase 3 trial in initial therapy.The company will host an in-person investor event with a live webcast on Dec 8, 2025 at 7:00 a.m. ET.

Syndax delivers $28.6M Revuforj sales, secures FDA Priority Review for NPM1 AML indication. Partner reports $36.2M Niktimvo revenue. See full results.

Specialised Therapeutics (ST) has expanded its partnership with Incyte to distribute two additional oncology therapies - axatilimab (Niktimvo) and retifanlimab (Zynyz) - in Australia, New Zealand, and Singapore. These medicines join the existing portfolio of Minjuvi and Pemazyre. Axatilimab, approved by FDA in August 2024, treats chronic graft-versus-host disease in patients who've had at least two prior treatments. Retifanlimab is approved for treating squamous cell carcinoma of the anal canal and Merkel cell carcinoma, with Australia having the highest MCC incidence globally. Under the agreement, Incyte will handle development and manufacturing, while ST will manage regulatory affairs, distribution, and local marketing. ST plans to submit both drugs for regulatory and reimbursement approval in 2025.